- Datum17.03.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
Puma Biotechnology Inc. Aktie
Verkaufen
Kaufen
Puma Biotechnology Inc. Chart
Puma Biotechnology Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Tradegate | VK | |||||
| TTMzero Indikation | VK | |||||
| Nasdaq | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,60 %
Intraday
-5,41 %
1 Woche
16,08 %
1 Monat
8,85 %
Seit Jahresbeginn
-33,60 %
1 Jahr
22,06 %
3 Jahre
-55,91 %
5 Jahre
Wikifolio
Passender Service zu Puma Biotechnology Inc.
Webinar zu Puma Biotechnology Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,225-6,055
- Jahrestief / Hoch ($)2,690-4,060
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Puma Biotechnology Inc.
Keine Dividenden verfügbar
Termine von Puma Biotechnology Inc.
Keine aktuellen Termine
Beschreibung
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
